Stoke Therapeutics (STOK) EBT Margin: 2022-2025
Historic EBT Margin for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -372.70%.
- Stoke Therapeutics' EBT Margin rose 16735.00% to -372.70% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.63%, marking a year-over-year increase of 64973.00%. This contributed to the annual value of -242.74% for FY2024, which is 95162.00% up from last year.
- Per Stoke Therapeutics' latest filing, its EBT Margin stood at -372.70% for Q3 2025, which was down 119.29% from -169.96% recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' EBT Margin ranged from a high of 71.99% in Q1 2025 and a low of -1,237.20% during Q2 2023.
- In the last 3 years, Stoke Therapeutics' EBT Margin had a median value of -531.88% in 2024 and averaged -508.88%.
- In the last 5 years, Stoke Therapeutics' EBT Margin tumbled by 47,292bps in 2023 and then spiked by 91,632bps in 2024.
- Over the past 4 years, Stoke Therapeutics' EBT Margin (Quarterly) stood at -786.32% in 2022, then plummeted by 17,724bps to -963.56% in 2023, then surged by 91,632bps to -47.24% in 2024, then spiked by 16,735bps to -372.70% in 2025.
- Its EBT Margin was -372.70% in Q3 2025, compared to -169.96% in Q2 2025 and 71.99% in Q1 2025.